Relationship of Sleep to Pulmonary Function in Mucopolysaccharidosis II - 23/05/13
, Joseph Muenzer, MD, PhD 2, Bradley V. Vaughn, MD 3, Marianne S. Muhlebach, MD 4
Reprint requests: William I. Wooten, III, MD, Department of Pediatrics, Division of Pulmonology, University of North Carolina at Chapel Hill, 450 MacNider Hall, Campus Box #7217, Chapel Hill, NC 27599-7217.Abstract |
Objective |
To study the sleep characteristics, pulmonary function, and their relationships in an enzyme naive population of patients with mucopolysaccharidoses (MPS) II (Hunter syndrome).
Study design |
The analyzed subjects (30 patients with MPS II with a median age of 9 years) had been enrolled in an MPS II natural history study and a phase I/II enzyme replacement clinical study in which they underwent standard polysomnography including spirometry and plethysmography, if cooperative. Descriptive statistics and nonparametric correlation were performed for demographic, sleep, and pulmonary function variables.
Results |
Median apnea-hypopnea index was 6.4, with obstructive sleep apnea observed in 27/30 subjects. Sleep architecture was characterized by diminished rapid-eye movement sleep duration (median 13%), and decline in sleep efficiency and slow-wave sleep duration in older individuals. Oxygen desaturation below 90% occurred in 26/30 subjects, and hypoventilation above 50 Torr occurred in 11/23 subjects with accurate end-tidal carbon dioxide recordings. Of 15 subjects with reliable spirometry, median forced expiratory volume in 1 second was below 80% predicted in 12/15 subjects. Forced expiratory volume in 1 second in percent-predicted was inversely related to apnea-hypopnea index and increase from baseline end-tidal carbon dioxide (P = .023, rs= −0.58), (P < .001, rs = −0.82).
Conclusion |
Sleep in MPS II is characterized by obstructive sleep apnea, altered sleep architecture, and impaired gas exchange. Sleep disruption is related to daytime pulmonary function, thus both systems should be evaluated when sleep abnormalities are suspected.
Le texte complet de cet article est disponible en PDF.Keyword : AHI, BMI, CPAP, ETCO2, ERT, FEV1, FEV1 %, FVC, GAG, MPS, OSA, REM, RV/TLC, SpO2, SWS, TLC
Plan
| J.M. was the principal investigator for both the MPS II phase I/II enzyme replacement clinical trial and the MPS II natural history studies at UNC, and has served as a consultant to Shire Human Genetic Therapies, Inc (Cambridge, MA) for the development of enzyme replacement therapy for the treatment of MPS II. B.V. has received funding from Glaxo Smith Kline and Johns Hopkins University for research in Restless Legs Syndrome. The other authors declare no conflicts of interest. |
Vol 162 - N° 6
P. 1210-1215 - juin 2013 Retour au numéro
Article précédent
- N-Terminal Pro-Brain Natriuretic Peptide and Risk of Coronary Artery Lesions and Resistance to Intravenous Immunoglobulin in Kawasaki Disease
- Ken Yoshimura, Takahisa Kimata, Kenji Mine, Takamichi Uchiyama, Shoji Tsuji, Kazunari Kaneko
- A Prospective Randomized Trial on Preventative Methods for Positional Head Deformity: Physiotherapy versus a Positioning Pillow
- Jan-Falco Wilbrand, Maximilian Seidl, Martina Wilbrand, Philipp Streckbein, Sebastian Böttger, Joern Pons-Kuehnemann, Andreas Hahn, Hans-Peter Howaldt
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?